Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory Multiple Myeloma

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 8, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, Oct. 8, 2024 -- Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online Oct. 4 in Blood.

Surbhi Sidana, M.D., from Stanford University in California, and colleagues reported outcomes with cilta-cel in the standard-of-care setting. The analysis included 255 patients with RRMM who underwent leukapheresis for cilta-cel manufacturing from March through December 2022 at 16 U.S. academic medical centers.

The researchers found that of the leukapheresed patients, 56 percent would not have met CARTITUDE-1 trial eligibility criteria. Manufacturing failure rates were 6 percent at first attempt and 1 percent overall, respectively. Patients had received a median of six prior lines of therapy. Among the 236 treated patients, cytokine release syndrome was seen in 75 percent (grade ≥3: 5 percent), immune effector cell-associated neurotoxicity syndrome in 14 percent (grade ≥3: 4 percent), and delayed neurotoxicity in 10 percent. Best overall rates and complete response or better rates, respectively, were 89 and 70 percent in infused patients (236 patients), 94 and 74 percent in patients receiving conforming CAR T-cell product (191 patients), and 95 and 76 percent in patients receiving conforming CAR T-cell product with fludarabine/cyclophosphamide lymphodepletion (152 patients). Infection was the most common reason for nonrelapse mortality (10 percent). After a median 13 months of follow-up, median progression-free survival (PFS) was not reached, with a 12-month estimate of 68 percent. There was an independent association between high ferritin levels, high-risk cytogenetics, and extramedullary disease with inferior PFS, with a signal for prior B-cell maturation antigen-targeted therapy. Excluding nonmelanoma skin cancers, second primary malignancies (SPMs) were seen in 5.5 percent of patients and myeloid malignancies/acute leukemia was seen in 1.7 percent.

"Close surveillance for late complications like SPMs and efforts to mitigate delayed neurotoxicity and nonrelapse mortality are crucial," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Karyopharm Therapeutics, which manufactures cilta-cel.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-09 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords